SLS
Sellas Life Sciences Group Inc
NASDAQ: SLS · HEALTHCARE · BIOTECHNOLOGY
$4.95
+6.00% today
Updated 2026-04-30
Market cap
$900.52M
P/E ratio
—
P/S ratio
26.90x
EPS (TTM)
$-0.25
Dividend yield
—
52W range
$1 – $6
Volume
6.7M
Sellas Life Sciences Group Inc (SLS) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-66.90%
ROA
-34.70%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | — | $-2.40M | — | — | — |
| 2007 | — | $-10.99M | — | — | — |
| 2008 | — | $-14.37M | — | — | — |
| 2009 | — | $-18.39M | — | — | — |
| 2010 | — | $-11.99M | — | — | — |
| 2011 | $0.00 | $-11.48M | — | — | — |
| 2012 | $2.04M | $-34.97M | 100.00% | -1,040.19% | -1,715.85% |
| 2013 | $2.49M | $-76.68M | 79.09% | -1,360.68% | -3,083.15% |
| 2014 | $9.32M | $-36.61M | 84.94% | -392.81% | -392.81% |
| 2015 | $0.00 | $-63.90M | — | — | — |
| 2016 | $0.00 | $-23.55M | — | — | — |
| 2017 | $0.00 | $-23.75M | — | — | — |
| 2018 | $0.00 | $-27.67M | — | — | — |
| 2019 | $0.00 | $-19.29M | — | — | — |
| 2020 | $1900.00 | $-16.76M | 100.00% | -893,789.47% | -881,947.37% |
| 2021 | $7.60M | $-20.70M | 97.37% | -332.82% | -272.36% |
| 2022 | $1.00M | $-41.30M | 90.00% | -4,195.00% | -4,130.10% |
| 2023 | $0.00 | $-37.34M | — | — | — |
| 2024 | $0.00 | $-30.88M | — | — | — |
| 2025 | $0.00 | $-26.86M | — | — | — |